J82 Cells

Unit

3 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Urinary bladder cancer cell lines

Organism

Human

Donor History

Bladder carcinoma

Growth Properties

Adherent

Growth Conditions

Culture medium: EMEM (MEM Eagle)

,

w: 2 mM L-Glutamine

,

w: 2.2 g/L NaHCO3

,

w: EBSS (Cytion article number 820100a). Supplements: Supplement the medium with 10% FBS and 1% NEAA. Dissociation reagent: Accutase. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/J82-Cells/305055

SKU: 305055 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

The J82 cell line is derived from a human bladder transitional cell carcinoma, offering a robust in vitro model for studying urothelial cancer. These cells exhibit epithelial morphology and are adherent in culture, making them suitable for a variety of experimental applications, including cancer biology research, drug screening, and molecular analysis. J82 cells are known to express markers characteristic of bladder carcinoma, including cytokeratins, which are valuable for understanding the molecular pathways involved in bladder cancer progression and for identifying potential therapeutic targets.

The J82 cell line is particularly useful for studies focusing on the mechanisms of drug resistance, metastasis, and the role of genetic mutations in bladder cancer. Researchers have utilized this cell line to explore the effects of chemotherapeutic agents and to identify novel compounds that may inhibit cancer cell growth. Additionally, J82 cells are frequently used in gene expression studies to investigate the regulation of oncogenes and tumor suppressor genes within the context of bladder cancer. As with all cancer cell lines, J82 should be handled under strict laboratory conditions, ensuring its use is restricted to research applications and not for any therapeutic or in vivo purposes.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.